Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment
© Chen et al; licensee BioMed Central Ltd. 2011
Received: 4 October 2010
Accepted: 13 January 2011
Published: 13 January 2011
Methotrexate (MTX) is the most commonly prescribed disease-modifying antirheumatic drug (DMARD) in rheumatoid arthritis. ATP-binding cassette transporter-A1 (ABCA1) and 27-Hydroxylase (HY27) are known antiatherogenic proteins that promote cellular cholesterol efflux. In THP-1 macrophages, MTX can promote the reversal of cholesterol transport, limit foam cell formation and also reverse COX-2 inhibitor-mediated downregulation of ABCA1. Despite its antiatherogenic potential in vitro, the impact of clinical use of low-dose MTX on cholesterol metabolism in humans is unknown. Objective of the study was to examine whether clinical MTX use is associated with altered blood lipids and/or ABCA1/HY27 expressions.
In all, 100 rheumatoid arthritis subjects were recruited from a medical center in central Taiwan. Plasma lipid profiles and peripheral blood mononuclear cell HY27 and ABCA1 expressions were compared between subjects taking MTX (MTX+) and other disease-modifying antirheumatic drugs (DMARDs) (MTX-). Dietary intake was assessed by a registered dietician.
Though no difference observed in the blood lipids between MTX+ and MTX- subjects, the expressions of ABCA1 and HY27 were significantly elevated in MTX+ subjects (n = 67) compared to MTX- subjects (n = 32, p < 0.05). ABCA expression correlated with MTX doses (r = 0.205, p = 0.042), and MTX+ subjects are more likely to have increased HY27 compared to MTX- subjects (OR = 2.5, p = 0.038). Prevalence of dyslipidemia and overweight, and dietary fat/cholesterol intake were lower than that of the age-matched population. Although no differences were observed in the blood lipids, the potential impacts of MTX on cholesterol metabolism should not be overlooked and the atheroprotective effects from MTX induced HY27 and ABCA1 expressions may still be present in those persons with pre-existing dyslipidemia.
We demonstrated novel findings on the increased gene expressions of atheroprotective protein HY27 and ABCA1 in human peripheral blood mononuclear cells (PBMCs) with clinical use of low-dose MTX. Whether MTX induced HY27 and ABCA1 expressions can protect against cardiovascular disease in patients with chronic inflammation through the facilitation of cholesterol export remains to be established. Further studies on the impacts of low-dose MTX on hypercholesterolemic patients are underway.
Methotrexate (MTX) is the most commonly prescribed disease-modifying antirheumatic drug (DMARD) for human rheumatoid arthritis. MTX is a folate antagonist that inhibits dihydrofolate reductase activity and is used for its anti-inflammatory and immunosuppressive properties in rheumatoid arthritis . MTX blocks a number of enzymes involved in purine and pyrimidine metabolism. MTX promotes adenosine release and adenosine, acting at its receptors, mediates the immunologic and anti-inflammatory effects of MTX in the treatment of rheumatoid arthritis [2–4].
Dyslipidemia is the elevation of plasma cholesterol, triglycerides, or a low/high density lipoprotein that usually results from excessive dietary intake of saturated fat, cholesterol, or trans fats. We recently discovered in a pilot study that some arthritis patients on low dose MTX had altered blood lipids compared to those not taking methotrexate . We postulated that these altered blood lipid profile is related to the changes in ATP-binding cassette transporter A1 (ABCA1) and 27-hydroxylase (HY27), as a previous in vitro study reported that MTX induced HY27 expression and reversed cyclo-oxygenase 2 (COX-2) inhibitor-mediated downregulation of ABCA1 in a macrophage cell model.
The mitochondrial cytochrome P-450 sterol HY27 catalyzes the initial oxidation steps in the bile acid synthesis from cholesterol ; ABCA1 is a cell membrane-bound protein responsible for the secretion of excess cholesterol, phospholipids, and other lipophilic molecules across the plasma membrane from cells. Both HY27 and ABCA1 play crucial roles in cholesterol metabolism in most tissues of the body .
Atherosclerosis contributes to cardiovascular disease (CVD), morbidity, and mortality in autoimmune diseases, including: systemic lupus erythematosus and rheumatoid arthritis . Impaired cholesterol homeostasis has been reported in patients with rheumatoid arthritis and lupus erythematosus [8–10]. Incubation of systemic lupus erythematosus in patients' plasma significantly decreased the expression of HY27 in THP-1 human monocytes and further increased the THP-1 macrophage foam cell transformation from monocytes . These results imply a role of immune dysfunction in human atherogenesis, and certain immunological mediators may perturb the cholesterol homeostasis in human monocytes/macrophages and endothelium. By inhibiting the inflammatory response, MTX and other DMARDs may reduce the risk of CVD by decreasing the exposure of atherogenic mediators in these patients.
In vitro MTX treatment increases HY27 mRNA expression and blocks COX2 inhibitor-induced downregulation of HY27 in human THP-1 monocyte/macrophages . In THP-1 macrophages MTX has been reported to promote the reversal of cholesterol transport through adenosine A2A receptor activation and limits foam cell formation . In addition, MTX reverses COX-2 inhibitor-mediated downregulation of ABCA1, suggesting an atheroprotective effect of MTX . We hypothesized that clinical use of low-dose MTX in humans can alter blood lipid metabolism via induction of ABCA1 and 27HY.
The objective of the present study were to (1) compare the blood lipid profile as well as gene expression of these antiatherogenic proteins between subjects taking MTX (MTX+) and other DMARDs (MTX-), and (2) examine the associations among MTX dose, duration and lipid profiles, as well as the expression of ABCA1 and HY27 in the peripheral blood mononuclear cells (PBMCs) of humans with chronic inflammation.
A total of 100 adults (aged above 18 years) with rheumatoid arthritis fulfilling the American College of Rheumatology 1987 revised criteria for rheumatoid arthritis  were recruited prospectively from the Allergy, Immunology and Rheumatology outpatient clinic at the Department of Immunology and Rheumatology, Taichung Veterans General Hospital, Taiwan between 2007 and 2009. The study protocol was approved by the clinical research ethics committee, and informed consent was obtained from each participant prior to enrollment. Subjects with pregnancy, anemia (hemoglobin 10 mg/dL or lower), thrombocytopenia (platelet count below 50,000 cells/μL), abnormal serum hepatic transaminase (aspartate aminotransferase or alanine aminotransferase above 50 IU/L), renal insufficiency (serum creatinine above 1.5 mg/dL), diabetes or cancer were excluded. None of the study subjects were using antihyperlipidemic drugs during the study period. Blood chemistry and hematology screening were performed to ensure eligibility before enrollment. All patients were taking medications for rheumatoid arthritis symptom relief, and therefore disease activity was controlled during the study period. No changes in medication had been made for 1 month prior to enrollment for any of the subjects. Levels of C-reactive protein were determined by enzyme immunoassay  (Virgo C-reactive protein 150 kit; Hemagen, Waltham, Massachusetts, USA).
Human study experimental protocol
Subjects were asked to fast overnight for 12 h for the study blood draw. In the following morning, fasting blood samples from the subjects were collected into ethylenediaminetetraacetic acid (EDTA) tubes and chilled immediately on ice for the determination of total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and for RNA extraction from the PBMCs. Each patient was then instructed to complete the Stanford Health Assessment Questionnaire (HAQ) , which has 13 categories of questions that evaluate how well the patient is able to perform routine activities.
Plasma lipid profiles in subjects taking MTX and other DMARDs
Plasma total lipid was determined enzymatically with an autoanalyzer (Hitachi 7070; Hitachi, Tokyo, Japan) using clinical chemical kits (Wako Co, Osaka, Japan). TC, TG, HDL-C, LDL-C were determined by Randox reagent kit (Randox Laboratories Ltd, Crumlin, UK).
ABCA1 and HY27expression in human PBMCs
Dietary intake of study subjects
For assessment of dietary intake, subjects were instructed to complete a food record, and each subject was interviewed by a registered dietitian for validation of the food record  on the day of blood collection. A colored book with 1:1 size food photos were used to standardize portion size among subjects. Nutrient composition was calculated with the use of Nutritionist Professional software (E-kitchen Business Corporation, Taipei, Taiwan), in combination with the Taiwan food composition table, established by the Department of Health in Taiwan.
Statistical analyses were performed using SYSTAT software (Version 11.0) for Windows (SYSTAT, Richmond, CA, USA). Demographic and hematological data were compared by Mann-Whitney U test between the two groups. For categorical variables, differences between two groups were assessed by χ2 test. Pearson correlation coefficients were calculated between continuous variables including PBMC ABCA1 expression, HY27 expression, the MTX duration (months), and the MTX weekly dose (mg) in subjects taking low dose MTX. Odds ratios (ORs) with 95% confidence intervals (CI) for elevated (above the median) ABCA1 or HY27 gene expression were calculated from unconditional logistic regression models according to the MTX use or not. Results were defined statistically significant at p <0.05.
Demographic data of study subjects (n = 99)
Non-MTX users (n = 32)
MTX users (n = 67)
53.0 (49.0 to 58.0)
53.0 (50.3 to 57.0)
22.8 (21.6 to 24.4)
21.8 (21.6 to 23.5)
WBC count, cells/mm3
6,400 (5,536 to 6,844)
5,900 (5,980 to 6,900)
12.9 (11.7 to 13.2)
12.6 (12.2 to 12.9)
Serum creatinine, mg/dl
0.90 (0.87 to 1.13)
0.80 (0.79 to 0.87)
15.0 (15.0 to 29.1)
16.0 (15.3 to 20.0)
0.40 (0.53 to 1.65)
0.22 (0.52 to 1.75)
Systolic BP, mmHg
130.0 (123.4 to 133.8)
129.0 (114.7 to 142.2)
Diastolic BP, mmHg
80.0 (76.2 to 82.3)
79.0 (65.8 to 92.7)
Disease duration, years
14.1 (11.5 to 16.8)
12.0 (11.3 to 15.0)
Disease activity, HAQ
0.187 (0.11 to 0.80)
0.125 (0.20 to 0.49)
Physical activity, h/week
0.00 (0.37 to 3.85)
0.50 (1.14 to 2.41)
Weekly dose, mg
12.5 (10.5 to 12.5)
36.0 (45.8 to 77.8)
Weekly dose, mg
43.7 (35.0 to 48.7)
35.0 (38.9 to 55.3)
34.0 (32.6 to 105.8)
48.0 (46.4 to 79.2)
Weekly dose, mg
7,000 (7,882 to 11,233)
7,000 (9,051 to 11,825)
53.5 (38.8 to 105.1)
50.0 (51.5 to 86.4)
Weekly dose, mg
1,404 (1,404 to 1,968)
1,400 (1,486 to 1,804)
11.5 (9.2 to 15.7)
13.0 (13.6 to 21.6)
Weekly dose, mg
1,400 (1,581 to 2,250)
1,400 (1,561 to 2,005)
18.0 (14.0 to 30.8)
23 (-8.7 to 123.8)
Weekly dose, mg
105 (78.6 to 110.3)
105 (78.8 to 98.8)
7.5 (0.78 to 23.6)
12.0 (9.6 to 27.4)
Plasma lipid profiles in subjects with or without low-dose MTX treatments
Blood lipid profiles and cholesterol metabolic gene expressions in study subjects
Non-MTX users (n = 32)
MTX users (n = 67)
167.5 (162.8 to 192.4)
172.0 (169.3 to 185.5)
81.0 (75.7 to 105.1)
71.0 (73.2 to 90.7)
1.34 (1.25 to 1.71)
1.38 (1.30 to 1.59)
66.0 (59.4 to 71.8)
69.0 (65.0 to 74.0)
85.7 (79.6 to 102.6)
89.0 (85.8 to 99.9)
2.72 (2.51 to 3.07)
2.60 (2.53 to 2.88)
0.09 (0.03 to 0.77)
0.15 (0.43 to 2.60)
0.07 (-0.05 to 1.41)
0.19 (0.32 to 5.40)
ABCA1 and HY27 expression in human PBMCs
Stratified analysis between methotrexate (MTX) use and elevated ATP-binding cassette transporter A1 (ABCA1) and 27-hydroxylase expression in study subjects
OR (95% CI)
No (n = 32)
Yes (n = 67)
1.94 (0.82 to 4.58)
No (n = 32)
Yes (n = 67)
2.50 (1.04 to 6.01)
Dietary intake in study subjects
Non-MTX users (n = 32)
MTX users (n = 67)
1,248 (1,158 to 1,507)
1,249 (1,184 to 1,419)
183.5 (155.9 to 275.2)
174.5 (174.2 to 216.9)
Percentage of energy
51.1 (19.9 to 141.0)
38.9 (38.3 to 45.8)
Percentage of energy
43.9 (11.0 to 133.8)
38.6 (36.2 to 45.0)
Percentage of energy
243.8 (109.4 to 178.4)
223.6 (77.1 to 516.1)
Most subjects (approximately 80%) of the present study had a daily cholesterol intake below 300 mg and only 7% had high fat intake (>65 g/day). These results indicated that our subjects had relatively healthy dietary habits, which may have contributed to the relatively normal blood lipid profiles in these subjects compared to those of the general healthy population [20–22]. The average time of physical activity (h) did not differ between the two groups.
This study demonstrated that clinical use of MTX for treating rheumatoid arthritis is associated with elevated expressions of atheroprotective protein HY27 and ABCA1 in human PBMCs. This is the first in vivo evidence in humans that the commonly used low-dose MTX in rheumatoid arthritis might induce the mRNA expression of antiatherogenic reverse cholesterol transporter expression in humans. Via the induction of these proteins, low-dose MTX treatment has the potential to protect against dyslipidemia through facilitation of cholesterol outflow in patients on this medication.
In the present study, no significant differences in blood lipids were observed between MTX(+) and MTX(-) subjects, possibly attributed to low prevalence of dyslipidemia in the study subjects. Although no differences were observed in the blood lipid profiles, the potential impacts of MTX on cholesterol metabolism should not be overlooked. The majority of our subjects had relatively normal cholesterol intake, and their lipid indicators fell within the normal range of healthy humans. We suggest that the potential impacts of altered HY27 and ABCA1 might be compensated by relatively normal cholesterol intake in these subjects. It is plausible that the potential atheroprotective effects from HY27 and ABCA1 inductions occur only in those persons with elevated blood lipids. This postulation needs to be investigated further in animals or subjects with abnormal blood lipids in the future.
According to the latest 2005-2008 NAHSIT, the prevalence of hyperlipidemia, hypertriglyceridemia, elevated LDL-C, and low HDL-C in females at the same age group were 4.7%, 11.8%, 18.6%, and 2.9%, respectively . The prevalence of abnormal lipid profiles was determined by the standard for the threshold limit value of disease (TC ≥240 mg/dl, TG ≥200 mg/dl, HDL-C <35 mg/dl, LDL-C≥160 g/dl) . When the same standard was applied to subjects in the present study, less than 5% of our subjects had elevated TC (4%) or TG (2%), elevated LDL-C (2%) or low HDL-C (2%), indicating that the prevalence of abnormal blood lipid profile in these subjects was indeed lower than that of the general Taiwanese population of the same age. When we looked at the prevalence of marginal elevated blood lipid profiles using the normal range of healthy humans (mean TC <200 mg/dl; TG <150 mg/dl; HDL-C >40 mg/dl; LDL-C <130 g/dl), the prevalence of dyslipidemia in our subjects was also lower than that in the NAHSIT . Only 24.2% of our subjects had elevated TC, 6.1% had elevated TG, 5.1% had low HDL-C, and 12.1% had elevated LDL-C. Consistently, we found a lower prevalence of being overweight (24≤BMI <27 kg/m2) and obesity (≥27 kg/m2) in our study subjects (19% for being overweight and 16% for obesity) that was also lower than that of the general population at a similar age (39% for being overweight and 23% for obesity) in Taiwan .
The therapeutic strategies for dyslipidemia include a healthy diet with reduced intake of saturated fat and cholesterol. With regard to cholesterol intake, most of our subjects (79.6%) had a daily cholesterol intake below 300 mg (Table 4). In addition, only approximately one-fifth of these subjects had fat intake exceeding 30% of their total calories and, on average, 29% of the total energy came from fat. In the general population of the same age, the prevalence of high fat intake was up to 46.5%, and the energy from fats was 35% . The mean intake of saturated fat in our study subjects was also significantly lower than that of the population . We concluded that lower cholesterol and fat intake accounted for the relatively normal blood lipid profiles in these subjects.
In vitro MTX treatment was shown to increase HY27 mRNA expression  and reverse the COX2 inhibitor-induced downregulation of HY27 and ABCA1 in human THP-1 monocyte/macrophages . Despite no differences being observed in the blood lipid profiles between MTX(-) and MTX(+) subjects, we found that clinical use of low-dose MTX was associated with increased HY27 and ABCA1 mRNA in the PBMCs. These results implied that under certain conditions, clinical use of MTX might induce the gene expression of atheroprotective protein HY27 and ABCA1. This is the first in vivo evidence that the commonly used DMARD MTX may increase the expression of antiatherogenic reverse cholesterol transport protein in human PBMCs. However, the potential impacts of MTX induced HY27 and ABCA1 expressions might be compensated by relatively normal to low cholesterol intake in these subjects; and that the potential atheroprotective effects from HY27 and ABCA1 may only be present in those persons with pre-existing dyslipidemia. Whether MTX induced HY27 and ABCA1 expressions can protect against cardiovascular disease in patients with chronic inflammation through the facilitation of cholesterol export remains to be established. Further studies pertaining to the potential benefits of low-dose MTX in hypercholesterolemic subjects are warranted.
We demonstrated novel findings on the increased gene expressions of atheroprotective protein HY27 and ABCA1 in human PBMCs in subjects taking low-dose MTX for treating chronic inflammation. Although there is no direct evidence from this study that MTX may improve lipid profile, this is the first in vivo evidence in humans that the commonly used low-dose MTX in rheumatoid arthritis might induce the mRNA expressions of antiatherogenic reverse cholesterol transporters in humans. Via the induction of these proteins, low-dose MTX treatment has the potential to protect against dyslipidemia through facilitation of cholesterol outflow in patients on this medication. Further studies on the impacts of low-dose MTX on hypercholesterolemia are underway.
E-PIC, H-MC, H-YC, W-WC: Department of Food Science & Biotechnology, National Chung Hsing University, Taichung, Taiwan
H-MC:Department of Nursing and Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan
D-YC, J-LL: Division of Allergy Immunology Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan
D-YC, J-LL: National Yang-Ming University, Taipei, Taiwan
D-YC: Chung-Shan Medical University, Taichung, Taiwan
The authors thank Hsien-Hua Hsieh and Lan-Ying Lu (Dept Food Science Technology at NCHU) for their assistance in subject recruiting and clinical data acquisition. Thanks are also given to the staff at the Department of Allergy, Immunology and Rheumatology, Department of Nursing, and the Clinical Chemistry Laboratory at Taichung Veterans General Hospital for general support. This project was supported in part by National Science Council (NSC98-2320-B005-004MY3, E-PIC) and by the Department of Health in Taiwan (DOH 97-TD-D-113-97011, E-PIC), and TCVGH-NCHU 997608 (E-PIC).
- Ward JR: Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1985, 12 (Suppl 12): 3-6.PubMed
- Chan ES, Cronstein BN: Methotrexate--how does it really work?. Nat Rev Rheumatol. 2010, 6: 175-178. 10.1038/nrrheum.2010.5.PubMedView Article
- Tian H, Cronstein BN: Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007, 65: 168-173.PubMed
- Chan ES, Fernandez P, Cronstein BN: Methotrexate in rheumatoid arthritis. Exp Rev Clin Immunol. 2007, 3: 27-33. 10.1586/1744666X.3.1.27.View Article
- Chih HM, Chang HY, Chen DY, Lan JL, Chiang EP: Low-dose methotrexate treatment is associated with increased total cholesterol and HDL-cholesterol in blood: a pilot study (Chinese). Nutri Sci J.
- Bjorkhem I, Danielsson H: Biosynthesis and metabolism of bile acids in man. Prog Liver Dis. 1976, 5: 215-231.PubMed
- Bjorkhem I: Mechanism of bile acid biosynthesis in mammalian liver. Sterols and Bile Acids. Edited by: Danielsson H, Sjovall J. 1985, Amsterdam, The Netherlands: Elsevier Science Publishers, 231-278. full_text.View Article
- Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2399-2406. 10.1056/NEJMoa035471.PubMedView Article
- Salmon JE, Roman MJ: Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008, 121: S3-S8. 10.1016/j.amjmed.2008.06.010.PubMedPubMed CentralView Article
- Reiss AB: Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep. 2009, 11: 255-260. 10.1007/s11926-009-0036-y.PubMedView Article
- Reiss AB, Anwar K, Merrill JT, Chan ES, Awadallah NW, Cronstein BN, Michael Belmont H, Belilos E, Rosenblum G, Belostocki K, Bonetti L, Hasneen K, Carsons SE: Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int. 2010, 30: 591-598. 10.1007/s00296-009-1020-6.PubMedPubMed CentralView Article
- Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, Fernandez P, Cronstein BN, Chan ES: Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008, 58: 3675-3683. 10.1002/art.24040.PubMedPubMed CentralView Article
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.PubMedView Article
- Chiang EP, Bagley PJ, Selhub J, Nadeau M, Roubenoff R: Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med. 2003, 114: 283-287. 10.1016/S0002-9343(02)01528-0.PubMedView Article
- Fries JF, Spitz PW, Young DY: The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982, 9: 789-793.PubMed
- Chiang EP, Wang YC, Chen WW, Tang FY: Effects of insulin and glucose on cellular metabolic fluxes in homocysteine transsulfuration, remethylation, S-adenosylmethionine synthesis, and global deoxyribonucleic acid methylation. J Clin Endocrinol Metab. 2009, 94: 1017-1025. 10.1210/jc.2008-2038.PubMedView Article
- Chiang EP, Bagley PJ, Roubenoff R, Nadeau M, Selhub J: Plasma pyridoxal 5'-phosphate concentration is correlated with functional vitamin B-6 indices in patients with rheumatoid arthritis and marginal vitamin B-6 status. J Nutr. 2003, 133: 1056-1059.PubMed
- Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R: Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther. 2005, 7: R1254-R1262. 10.1186/ar1821.PubMedPubMed CentralView Article
- Chiang EP, Selhub J, Bagley PJ, Dallal G, Roubenoff R: Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R1404-R1411. 10.1186/ar1839.PubMedPubMed CentralView Article
- Pan WH, Chiang BN: Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan--a unique experience. Atherosclerosis. 1995, 118: 285-95. 10.1016/0021-9150(95)05616-5.PubMedView Article
- Pan WH, Chang YH, Chen JY, Wu SJ, Tzeng MS, Kao MD: Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996: Dietary Nutrient Intakes Assessed by 24-Hour Recall. Nutr Sci J. 1999, 24: 11-39.
- Taiwanese Department of Health: Nutrition and Health Survey in Taiwan (NAHSIT) 2005-2008. [http://www.doh.gov.tw]
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/9/4/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.